Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Cornelissen, Robin ^a   Lievense, Lysanne A ^a   Maat, Alexander P ^a   Hendriks, Rudi W ^a   Hoogsteden, Henk C ^a   Bogers, Ad J ^a   Hegmans, Joost P ^a   Aerts, Joachim G ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; AGE; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CD163/CD68 RATIO; CD8+ T LYMPHOCYTE; CD8+ TUMOR INFILTRATING LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; EORTC SCORE; EPITHELIOID MALIGNANT PLEURAL MESOTHELIOMA; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INDUCTION CHEMOTHERAPY; LYMPHOCYTE COUNT; MACROPHAGE; MALE; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; SCORING SYSTEM; SEX; TUMOR ASSOCIATED LEUKOCYTE; ADULT; IMMUNOLOGY; LUNG TUMOR; MESOTHELIOMA; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PHENOTYPE; PLEURA TUMOR; PROGNOSIS; TUMOR MICROENVIRONMENT;

CD163 ANTIGEN; CD68 ANTIGEN, HUMAN; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN; MEMBRANE ANTIGEN;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTIGENS, SURFACE; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; PHENOTYPE; PLEURAL NEOPLASMS; PROGNOSIS; RECEPTORS, CELL SURFACE; TUMOR MICROENVIRONMENT;

EID: 84907000329     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106742     Document Type: Article

References (48)

1. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, et al. (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636-2644. doi:10.1200/JCO.2003.11.136
2. Van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, et al. (2005) Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23: 6881-6889. doi:10.1200/JCO.20005.14.589
3. Flores RM, Pass HI, Seshan VE, Dycoco J, Zakowski M, et al. (2008) Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 135: 620-626, 626.e1-3. doi:10.1016/j.jtcvs.2007.10.054
4. Alexander HR Jr, Bartlett DL, Pingpank JF, Libutti SK, Royal R, et al. (2013) Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery 153: 779-786. doi:10.1016/j.surg.2013.01.001
5. Haas AR, Sterman DH (2013) Malignant Pleural Mesothelioma. Clinics in Chest Medicine 34: 99-111. doi:10.1016/j.ccm.2012.12.005
6. Gordon GJ, Dong L, Yeap BY, Richards WG, Glickman JN, et al. (2009) Fourgene expression ratio test for survival in patients undergoing surgery for mesothelioma. Journal of the National Cancer Institute 101: 678-686.
7. Suzuki K, Kadota K, Sima CS, Sadelain M, Rusch VW, et al. (2011) Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients. Cancer Immunology, Immunotherapy 60: 1721-1728. doi:10.1007/s00262-011-1073-8
8. Yamada N, Oizumi S, Kikuchi E, Shinagawa N, Konishi-Sakakibara J, et al. (2010) CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection. Cancer Immunology, Immunotherapy 59: 1543-1549. doi:10.1007/s00262-010-0881-6
9. Anraku M, Cunningham KS, Yun Z, Tsao M-S, Zhang L, et al. (2008) Impact of tumor-infiltrating T cells on survival in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg 135: 823-829. doi:10.1016/j.jtcvs.2007.10.026
10. Cornelissen R, Heuvers ME, Maat AP, Hendriks RW, Hoogsteden HC, et al. (2012) New Roads Open Up for Implementing Immunotherapy in Mesothelioma. Clinical and Developmental Immunology: 1-13. doi:10.1155/2012/927240
11. Burt BM, Rodig SJ, Tilleman TR, Elbardissi AW, Bueno R, et al. (2011) Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma. Cancer 117: 5234-5244. doi:10.1002/cncr.26143
12. Lan C, Huang X, Lin S, Huang H, Cai Q, et al. (2012) Expression of M2-Polarized Macrophages is Associated with Poor Prognosis for Advanced Epithelial Ovarian Cancer. Technol Cancer Res Treat.
13. Cui Y-L, Li H-K, Zhou H-Y, Zhang T, Li Q (2013) Correlations of Tumorassociated Macrophage Subtypes with Liver Metastases of Colorectal Cancer. Asian Pac J Cancer Prev 14: 1003-1007.
14. Medrek C, Pontén F, Jirström K, Leandersson K (2012) The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC cancer 12: 306.
15. Herwig MC, Bergstrom C, Wells JR, Höller T, Grossniklaus HE (2013) M2/M1 ratio of tumor associated macrophages and PPAR-gamma expression in uveal melanomas with class 1 and class 2 molecular profiles. Exp Eye Res 107: 52-58. doi:10.1016/j.exer.2012.11.012
16. Niino D, Komohara Y, Murayama T, Aoki R, Kimura Y, et al. (2010) Ratio of M2 macrophage expression is closely associated with poor prognosis for Angioimmunoblastic T-cell lymphoma (AITL). Pathol Int 60: 278-283. doi:10.1111/j.1440-1827.2010.02514.x
17. Becker M, Müller CB, De Bastiani MA, Klamt F (2013) The prognostic impact of tumor-associated macrophages and intra-tumoral apoptosis in non-small cell lung cancer. Histol Histopathol.
18. Mantovani A, Sica A (2010) Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 22: 231-237. doi:10.1016/j.coi.2010.01.009
19. Lievense LA, Bezemer K, Aerts JGJV, Hegmans JPJJ (2013) Tumor-associated macrophages in thoracic malignancies. Lung Cancer. doi:10.1016/j.lungcan. 2013.02.017
20. Fennell DA (2004) Statistical Validation of the EORTC Prognostic Model for Malignant Pleural Mesothelioma Based on Three Consecutive Phase II Trials. Journal of Clinical Oncology 23: 184-189. doi:10.1200/JCO.2005.07.050
21. Hegmans JPJJ, Hemmes A, Hammad H, Boon L, Hoogsteden HC, et al. (2006) Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur Respir J 27: 1086-1095. doi:10.1183/09031936.06.00135305
22. Heusinkveld M, van der Burg SH (2011) Identification and manipulation of tumor associated macrophages in human cancers. Journal of Translational Medicine 9: 216. doi:10.1186/1479-5876-9-216
23. Brower V (2012) Macrophages: cancer therapy's double-edged sword. J Natl Cancer Inst 104: 649-652. doi:10.1093/jnci/djs235
24. Schmid MC, Varner JA (2010) Myeloid cells in the tumor microenvironment: modulation of tumor angiogenesis and tumor inflammation. J Oncol 2010:201026. doi:10.1155/2010/201026
25. Ruffell B, Affara NI, Coussens LM (2012) Differential macrophage programming in the tumor microenvironment. Trends Immunol 33: 119-126. doi:10.1016/j.it.2011.12.001
26. Bremnes RM, Al-Shibli K, Donnem T, Sirera R, Al-Saad S, et al. (2011) The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. J Thorac Oncol 6: 824-833. doi:10.1097/JTO.0-b013e3182037b76
27. De Kleijn S, Langereis JD, Leentjens J, Kox M, Netea MG, et al. (2013) IFN-cstimulated neutrophils suppress lymphocyte proliferation through expression of PD-L1. PLoS ONE 8: e72249. doi:10.1371/journal.pone.0072249
28. Topalian SL, Drake CG, Pardoll DM (2012) Targeting the PD-1/B7-H1(PDL1) pathway to activate anti-tumor immunity. Current Opinion in Immunology 24: 207-212. doi:10.1016/j.coi.2011.12.009
29. Taube JM, Anders RA, Young GD, Xu H, Sharma R, et al. (2012) Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape. Science Translational Medicine 4: 127ra37-127ra37. doi:10.1126/scitranslmed.3003689
30. Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, et al. (2009) Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. European Respiratory Journal 35: 479-495. doi:10.1183/09031936.00063109
31. Edin S, Wikberg ML, Dahlin AM, Rutegård J, Öberg Å, et al. (2012) The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PLoS One 7: e47045.
32. Pantano F, Berti P, Guida FM, Perrone G, Vincenzi B, et al. (2013) The role of macrophages polarization in predicting prognosis of radically resected gastric cancer patients. J Cell Mol Med 17: 1415-1421. doi:10.1111/jcmm.12109
33. Kaimala S, Mohamed YA, Nader N, Issac J, Elkord E, et al. (2014) Salmonellamediated tumor regression involves targeting of tumor myeloid suppressor cells causing a shift to M1-like phenotype and reduction in suppressive capacity. Cancer Immunol Immunother 63: 587-599. doi:10.1007/s00262-014-1543-x
34. Soini Y, Kahlos K, Puhakka A, Lakari E, Säily M, et al. (2000) Expression of inducible nitric oxide synthase in healthy pleura and in malignant mesothelioma. Br J Cancer 83: 880-886. doi:10.1054/bjoc.2000.1384
35. Tanaka S, Choe N, Hemenway DR, Zhu S, Matalon S, et al. (1998) Asbestos inhalation induces reactive nitrogen species and nitrotyrosine formation in the lungs and pleura of the rat. J Clin Invest 102: 445-454. doi:10.1172/JCI3169
36. Veltman JD, Lambers MEH, van Nimwegen M, Hendriks RW, Hoogsteden HC, et al. (2010) Zoledronic acid impairs myeloid differentiation to tumourassociated macrophages in mesothelioma. Br J Cancer 103: 629-641. doi:10.1038/sj.bjc.6605814
37. Popivanova BK, Kostadinova FI, Furuichi K, Shamekh MM, Kondo T, et al. (2009) Blockade of a chemokine, CCL2, reduces chronic colitis-associated carcinogenesis in mice. Cancer Res 69: 7884-7892. doi:10.1158/0008-5472.CAN-09-1451
38. Rogers TL, Holen I (2011) Tumour macrophages as potential targets of bisphosphonates. J Transl Med 9: 177. doi:10.1186/1479-5876-9-177
39. Tang X, Mo C, Wang Y, Wei D, Xiao H (2013) Anti-tumour strategies aiming to target tumour-associated macrophages. Immunology 138: 93-104. doi:10.1111/imm.12023
40. Biswas SK, Mantovani A (2010) Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 11: 889-896. doi:10.1038/ni.1937
41. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, et al. (2011) CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331: 1612-1616. doi:10.1126/science.1198443
42. Hagemann T, Lawrence T, McNeish I, Charles KA, Kulbe H, et al. (2008) "Reeducating" tumor-associated macrophages by targeting NF-kappaB. J Exp Med 205: 1261-1268. doi:10.1084/jem.20080108
43. Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP (2005) Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res 65: 3437-3446. doi:10.1158/0008-5472.CAN-04-4262
44. Fong CHY, Bebien M, Didierlaurent A, Nebauer R, Hussell T, et al. (2008) An antiinflammatory role for IKKbeta through the inhibition of "classical" macrophage activation. J Exp Med 205: 1269-1276. doi:10.1084/jem.20080124
45. Chuang C-M, Monie A, Hung C-F, Wu T-C (2010) Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination. J Biomed Sci 17: 32. doi:10.1186/1423-0127-17-32
46. Buhtoiarov IN, Sondel PM, Wigginton JM, Buhtoiarova TN, Yanke EM, et al. (2011) Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages. Immunology 132: 226-239. doi:10.1111/j.1365-2567.2010.03357.x
47. Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, et al. (2013) CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. doi:10.1038/nm.3337
48. Fridlender ZG, Kapoor V, Buchlis G, Cheng G, Sun J, et al. (2011) Monocyte chemoattractant protein-1 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ cells. Am J Respir Cell Mol Biol 44: 230-237. doi:10.1165/rcmb.2010-0080OC